⚡ Catalyst · Weekly Watchlist

REFRESH (prior report Aug 10, 2026) — DOWNGRADED to HOLD: Marvell's Investor Day is now officially confirmed for Oct 6, 2026 (7 days out), an upgrade in date provenance from the prior report's estimate. But the stock has run +19% since Aug 10 while the consensus target only grew modestly to $285.90 — upside has compressed to just +9.9%, below the threshold that supports a fresh BUY. This is a genuine, data-driven downgrade, not a rounding change: the thesis (AI custom silicon, NVIDIA partnership) is intact, but the margin of safety at today's price is thin. Base case (+8%) sits below the core lane's realized 14d P75 of +6.6% only marginally — this is the most 'measured-horizon-consistent' scenario in this refresh batch, reflecting how far the re-rating has already run.

REFRESH (prior report Aug 13, 2026): Q3 FY2026 earnings already passed (Sep 2) with a clean beat — EPS $3.32 vs $3.16 est. (+5.1%), revenue $29.59B (+85.5% YoY), the ninth consecutive beat. Despite that, the stock is down -15.9% since the last report, which reads as broad AI-semis multiple compression rather than an AVGO-specific problem. That drop widened consensus (50 analysts, Strong Buy) upside to +52.1% from $349.65 — the largest gap in this refresh batch. Next catalyst is Q4 FY2026 earnings, officially confirmed for Dec 10, 2026 (72 days out — beyond the near-term window, but the honest current state). Base case (+25%) sits above the core lane's realized 14d P75 of +6.6% — the gap reflects a multi-month re-rating horizon back toward the stock's own 52-week high, not near-term optimism bias.

REFRESH (prior report Aug 13, 2026) — CATALYST RESOLVED: the FDA approved ISEMBYLD (apitegromab-mstn) on Sep 11, 2026 — the first and only muscle-targeted SMA treatment, ahead of its Sep 30 PDUFA date. Jefferies raised its target to $65 (Buy) on the approval. Despite the positive outcome, the stock is roughly flat since Aug ($49.10 to $49.37) — the binary-event risk premium simply came out of the price rather than driving a fresh pop, consistent with a well-anticipated approval. The story is now commercial-execution, not regulatory-binary: the next catalyst is Q3 2026 earnings, the first quarter of real launch metrics. Consensus (Jefferies-anchored) $65 implies +31.7% upside from $49.37. Base case (+20%) is above the core lane's realized 14d P75 of +6.6% — the gap reflects a multi-quarter commercial-launch horizon, not optimism bias.

REFRESH (prior report Aug 13, 2026): Q4 FY2026 earnings already passed (Aug 27) with a milestone quarter — AI Cloud revenue ($70.5M) beat Bitcoin mining revenue ($66.7M) for the first time, and management guided to $4B+ ARR by the December quarter. The prior report's catalyst ('2027 capacity milestones,' 167 days out) was too vague to anchor a near-term trade; this refresh replaces it with the next quarterly print (Q1 FY27, no exact date yet confirmed). Consensus $77.97 implies +76.7% upside from $44.125, with JPMorgan citing 48% upside separately. Base case (+40%) is well above the core lane's realized 14d P75 of +6.6% — the gap reflects the multi-quarter ARR ramp horizon (FY27 capex guided at $25-30B), not near-term optimism bias.

Archer reports Q3 2026 earnings in the Nov 5-9, 2026 window (not yet officially confirmed to the exact day). The setup follows a Q2 2026 print where revenue surged 213% YoY to $5M and the Wisk Aero + Insitu acquisitions were announced, driving a standalone +15% pop, while the earnings reaction itself was muted (~-1%) amid sector-wide headline noise. Consensus target $11.63 (67% Buy) implies +107.3% upside from $5.61 — the largest upside in this batch, reflecting how far the stock has fallen (-35% YTD) versus a Street that hasn't fully cut targets. Base case (+45%) assumes reaffirmed certification progress and is well above the lane's realized 14d P75 of +6.6% — the gap is a multi-quarter re-rating horizon toward FAA type certification, not near-term optimism bias, and the specific driver is a certification-timeline update, not the Q3 numbers alone.

SoundHound reports Q3 2026 earnings on Nov 5, 2026 (confirmed). Its own last two prints show exactly how binary the reaction can be: Q1 2026 beat EPS but the stock fell -7.8% same day (-16% over the week) on dilution/offering concerns, while Q2 2026 beat and the stock jumped +15.4% after hours on clean guidance. Consensus target $12.71 (8 analysts, S&P Global; wider avg $13.29) implies +57.7% upside from $8.06. Base case (+35%) assumes a Q2-style clean beat and is well above the core lane's realized 14d P75 of +6.6% — the gap reflects a longer, multi-week re-rating horizon through and past the print, not the fixed measurement window, and the driver is guidance credibility, not just the EPS beat itself.

Satellogic's Merlin constellation begins launching in October 2026 (two NewSat Mark VI satellites with inter-satellite-link tech plus one NewSat Mark V), the first hard revenue-unlock event since the company guided to a ~$1B Space Systems pipeline. Since the last snapshot, two real catalysts landed: SynMax was named exclusive maritime partner for Merlin-constellation imagery (Sep 3), and Vice Admiral (Ret.) Frank Whitworth — former director of the National Geospatial-Intelligence Agency — was appointed President (Sep 8), a strong signal on government/defense scaling that the market rewarded with a +15.73% pop. Q2 2026 revenue grew 259% YoY to $15.9M with the company's first-ever positive operating income. Consensus target is now $10.20 (5 analysts, Strong Buy, high $11/low $9), +82.5% from $5.59 — narrower than the prior report's $8.90-15 range but confirms real analyst conviction survives the run. Base case (+55%) assumes a 3-4 month re-rating horizon through launch success and first commissioning data, not the 14-day North Star window — well above the core lane's realized 14d P75 of +6.6%, so read the gap as a horizon difference, not optimism bias.

Two things changed since the last snapshot: the Tempus AI partnership was extended and restructured (Sep 21, 2026) into committed, non-dilutive payments, and the REC-4881 FDA registrational-pathway update for familial adenomatous polyposis (FAP) remains the live near-term catalyst, now dated precisely to Oct 15, 2026 (previously badged inconsistently as 'H2 2026' against the same catalystDate — fixed in this refresh). Consensus (7 analysts, S&P Global) $7.22 implies +86.6% upside from $3.87, though Morgan Stanley's prior trim to $5.30 (Equal Weight) remains a real caution flag from a named, conservative voice. Base case (+35%) sits above the core lane's realized 14d P75 of +6.6% — the gap reflects the multi-month horizon to a registrational-pathway resolution, not near-term optimism bias.

The FDA has a Priority Review PDUFA decision due Nov 1, 2026 on mitapivat's supplemental NDA for sickle cell disease, backed by durable Phase 3 RISE UP data (lower transfusion needs, better PROs, clean safety). Agios has direct precedent: the same drug's thalassemia approval (Dec 2025) moved the stock +19.97% in a single session. Consensus target $42.33 (BofA $46, H.C. Wainwright $54, JPMorgan $31) implies +20.5% upside — the widened 20% gate is cleared, but with the thinnest margin of this batch given the target dispersion. Base case (+20%) sits near consensus and assumes approval on-label with no surprise; that's inside the lane's realized 14d P75 of +6.6% only if measured point-in-time — the written Base still assumes a multi-week re-rating horizon through the PDUFA date itself, not the fixed 14-day window.

Rivian's Q3 2026 production & delivery report is due in early October 2026 (exact day not yet officially set, but the company has released this data in the first days of each quarter all year — Q2 landed Jul 2). It's the first meaningful read on how the R2 ramp is scaling against the raised 65-70K FY delivery guide. Consensus target $19.31 (25 analysts, Hold; Wedbush's Dan Ives at $25 Outperform) implies +29.4% upside from $14.92 — the thinnest R/R of this batch, and the only 'Hold' consensus rating, but the imminent ~3-day catalyst window is the nearest-term event in this run. Base case (+15%) sits closest to the lane's realized 14d P75 (+6.6%) of any pick here — a shorter, more measurable horizon since the catalyst itself is days away, not weeks.